Shoulder Innovations, Inc. reported net revenue of $50.07 million for the nine months ended September 30, 2026, a significant increase from $32.90 million in the prior year period. Despite the revenue growth, the company incurred a net loss of $25.58 million for the period as it continues to invest heavily in research and development and selling, general, and administrative expenses.
Shoulder Innovations reported Q3 2026 revenue of $16.2 million, a 38% year-over-year increase driven by higher implant system sales and surgeon adoption. The company raised its full-year 2026 revenue guidance to a range of $68 million to $70 million and highlighted the commercial launch of its N-22 humeral head.
“Our third quarter results reflect the consistency of our commercial model, as we added new surgeons ahead of plan, grew volume within our existing customer base, and kept our product roadmap moving.”
Rob Ball, CEO of Shoulder Innovations
“This performance enabled us to again raise our outlook for the full year, and confirmed our conviction regarding our ability to grow market share through a differentiated approach to shoulder surgical care.”
Shoulder Innovations announced the limited user release and commercial launch of InSet Go, its next-generation glenoid implant for anatomic shoulder arthroplasty. The launch follows the successful completion of the first surgical case and aims to improve procedural efficiency while maintaining the company's clinically-proven design for implant stability.